Immunology Development News Today

This is an hour and 20 minutes. Okay, welcome welcome everyone to this talk with mike davis. It is exciting to see people joining from all over the country, all around the world really. It is exciting to have this chance to hear and engage with mike. And a longtime comrade, we are also both publishers of mike davis, very proud and we are teaming up to do a series of things during this pandemic crisis as part of our political, intellectual, Cultural Mission but also because we are on lockdown, tr...

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results from a first-of-its-kind study of lebrikizumab specifically designed for people with skin...

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced changes to its executive leadership team. Mike Mason, executive vice president and president...

Results show 26 weeks of treatment with twice-daily 60 mg dose of BMS-986278 resulted in a 69% relative reduction in the rate of decline in percent predicted forced vital capacity versus placeboTreatment effect was consistent with or without background therapy and BMS-986278 was well tolerated, with rates of adverse...

PRINCETON, N.J.--(BUSINESS WIRE)--Sep 9, 2023--

Results show 26 weeks of treatment with twice-daily 60 mg dose of BMS-986278 resulted in a 69% relative reduction in the rate of decline in percent predicted forced vital capacity versus...

Results show 26 weeks of treatment with twice-daily 60 mg dose of BMS-986278 resulted in a 69% relative reduction in the rate of decline in percent predicted forced vital capacity versus placebo Treatment effect was

Nimbus Therapeutics Appoints Nathalie Franchimont, M.D., Ph.D., as Chief Medical Officer - read this article along with other careers information, tips and advice on BioSpace